Royalty Pharma Plc buy PlusUltra
Start price
26.12.21
/
0%
€36.60
Target price
26.12.22
-
Performance (%)
13.99%
End price
15.09.22
€41.72
Summary
This prediction ended on 15.09.22 with a price of €41.72. The prediction had a final performance of 13.99%. This prediction was marked as speculative and is excluded from PlusUltra's performance statistics.Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Royalty Pharma Plc | - | - | - |
| iShares Core DAX® | 4.094% | 3.543% | 17.404% |
| iShares Nasdaq 100 | 1.424% | 0.512% | 39.212% |
| iShares Nikkei 225® | -1.572% | -4.633% | 15.731% |
| iShares S&P 500 | 1.822% | 0.963% | 30.396% |
According to PlusUltra what are the pros and cons of Royalty Pharma Plc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Undervalued
Very capable Management
Good culture
Very small cyclical dependencies
Future proof or reliable business model
Cons
Comments by PlusUltra for this prediction
In the thread Discuss Royalty Pharma Plc
Buy Royalty Pharma Plc